NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics). 

Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.

Definitions  
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.

NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. 

Faculty Disclaimers  
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

The NCCN staff listed below discloses no relevant financial relationships:
Kerrin M. Rosenthal, MA; Kimberly Callan, MS; Genevieve Emberger Hartzman, MA; Erin Hesler; Kristina M. Gregory, RN, MSN, OCN; Rashmi Kumar, PhD; Karen Kanefield; and Kathy Smith.

Individuals Who Provided Content Development and/or Authorship Assistance:
Robert J. Motzer, MD, Panel Chair, has disclosed that he receives grant/research support from Bristol-Myers Squibb Company, Eisai Inc., Exelixis Inc., Genentech/Roche, and Pfizer Inc.; and that he receives consulting fees from Eisai Inc., Eli Lilly and Company, Exelixis Inc., Incyte Corporation, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Genentech/Roche, and Pfizer Inc.
Eric Jonasch, MD, Panel Vice Chair, has disclosed that he receives consulting fees from Eisai Inc., Exelixis Inc., Genentech, Inc., Ipsen, Novartis Pharmaceuticals Corporation, and Pfizer Inc.; and the he receives grant/research support from Novartis Pharmaceuticals Corporation, Pfizer Inc., and Peloton Therapeutics, Inc.
M. Dror Michaelson, MD, PhD, Panel Member, has disclosed that he is a scientific advisor for Eisai Inc., Exelixis Inc., and Pfizer Inc.
Lakshminarayanan Nandagopal, MD, Panel Member, has disclosed that he has no relevant financial relationships.
John L. Gore, MD, MS, Panel Member, has disclosed that he receives grant/research support from Ferring Pharmaceuticals, Inc.
Saby George, MD, Panel Member, has disclosed that he receives grant/research support from Agensys Inc.; Astellas Pharma US, Inc.; Bayer Healthcare; Bristol-Myers Squibb Company; Eisai Inc.; Immunomedics, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; and Seattle Genetics, Inc. He also receives consulting fees from Bristol-Myers Squibb Company, EMD Serono, Exelixis Inc., and Pfizer Inc.
Ajjai Alva, MBBS, Panel Member, has disclosed that he receives grant/research support from AstraZeneca Pharmaceuticals LP, Bayer HealthCare, Bristol-Myers Squibb Company, Clovis Oncology, Janssen Pharmaceutica Products, LP, Merck & Co., Inc., Esanik, Ionis, Progfenics, and Prometheus; and that he receives consulting fees from AstraZeneca Pharmaceuticals LP, Bayer HealthCare, Merck & Co., Inc., and Progfenics.
Naomi Haas, MD, Panel Member, has disclosed that she was a scientific advisor for Pfizer Inc., and Roche Laboratories, Inc.
Michael R. Harrison, MD, Panel Member, has disclosed that he receives honoraria from Bayer HealthCare; receives grant/research support from Bristol-Myers Squibb Company, Exelixis Inc., Merck & Co., Inc., and Pfizer Inc.; receives consulting fees from Exelixis Inc., Genentech, Inc., and Janssen Pharmaceutica Products, LP; and is a scientific advisor for FujiFilm Corporation and Exelixis Inc.
Elizabeth R. Plimack, MD, MS, Panel Member, has disclosed that she receives grant/research support from Astellas Pharma US, Inc., Bristol-Myers Squibb Company, Genentech, Inc., Peloton Therapeutics, Inc., and Pfizer Inc.; and is a scientific advisor for and receives consulting fees from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Flatiron Health, Inc., Janssen Pharmaceutica Products, LP, Pfizer Inc., and Seattle Genetics, Inc.
Jeffrey Sosman, MD, Panel Member, has disclosed that he receives consulting fees from Genentech, Inc., and is a scientific advisor for and receives honoraria from Bristol-Myers Squibb Company.
Mary A. Dwyer, MS, CGC, Senior Manager, Guidelines, NCCN, has disclosed that she has no relevant financial relationships.
Lydia J. Hammond, MBA, Guidelines Layout Specialist, NCCN, has disclosed that she has no relevant financial relationships.
Griselda Zuccarino-Catania, PhD, Oncology Scientist/Medical Writer, NCCN, has disclosed that her spouse is employed by Janssen Pharmaceuticals, Inc.

To view all of the conflicts of interest for the panel, go to NCCN.org/disclosures/guidelinepanellisting.aspx.